← Natera overview

Natera vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Natera Inc (NTRA)

Q3 2026
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

July 2026
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

Latest
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

Q2 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

June 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

  • Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.

    Strong financial results directly boost investor confidence and the stock price.

  • Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.

    This major setback significantly impacted Regeneron's market value and reputation.

  • Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.

    The deal has both positive financial aspects and negative implications for Dupixent economics.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 2026
▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

© 2026 MarketIVWhy